Clinical trialNCT00393380TerminatedPhase 2Interventional

Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor

SponsorThe Emmes Company, LLCEnrollment13Anemia, AplasticHodgkin DiseaseLeukemia, Lymphocytic, AcuteLeukemia, Lymphocytic, ChronicLeukemia, Myelocytic, AcuteLeukemia, Myeloid, Chronic+2 more conditions

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine whether the addition of parathyroid hormone after a sequential cord blood transplant will improve engraftment, which is the ability of the transplanted stem cells to grow and to successfully begin producing new blood cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Colleen Delaney, MD
Fred Hutchinson Cancer Center
Principal Investigator
clinicaltrials.gov ↗
David Avigan, MD
Beth Israel Deaconess Medical Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Edward Ball, M.D.
University of California, San Diego
Principal Investigator
clinicaltrials.gov ↗
Elizabeth J Shpall, MD
MD Anderson Cancer Research Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Joseph Antin, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗
Karen K. Ballen, MD
Massachusetts General Hospital
Principal Investigator
clinicaltrials.gov ↗
Katarzyna Jamieson, M.D.
University of Florida
Principal Investigator
clinicaltrials.gov ↗
Philip McCarthy, M.D.
Roswell Park Cancer Institute
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
Ram Kamble, MD
Baylor College of Medicine
Principal Investigator
clinicaltrials.gov ↗
Richard Maziarz, M.D.
Oregon Health and Science University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Florida
Gainesville, Florida, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Massachusetts General Hospital
Boston, Massachusetts, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Parathyroid hormone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Sept 2006
Primary completion: 30 Nov 2009
Completion: 31 Mar 2012
Last update posted: 29 Apr 2013
Registered enrollment: 13
Registry id: NCT00393380

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.